JP2023540591A5 - - Google Patents

Info

Publication number
JP2023540591A5
JP2023540591A5 JP2023515363A JP2023515363A JP2023540591A5 JP 2023540591 A5 JP2023540591 A5 JP 2023540591A5 JP 2023515363 A JP2023515363 A JP 2023515363A JP 2023515363 A JP2023515363 A JP 2023515363A JP 2023540591 A5 JP2023540591 A5 JP 2023540591A5
Authority
JP
Japan
Prior art keywords
ifn
pharmaceutical preparation
administration
inhalation
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023515363A
Other languages
English (en)
Japanese (ja)
Other versions
JP7877300B2 (ja
JP2023540591A (ja
Filing date
Publication date
Priority claimed from GBGB2014114.9A external-priority patent/GB202014114D0/en
Application filed filed Critical
Publication of JP2023540591A publication Critical patent/JP2023540591A/ja
Publication of JP2023540591A5 publication Critical patent/JP2023540591A5/ja
Application granted granted Critical
Publication of JP7877300B2 publication Critical patent/JP7877300B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023515363A 2020-09-08 2021-09-07 全身性コルチコステロイドによる治療を受けているcopd患者におけるウイルス誘導性増悪を治療するための吸入インターフェロン-ベータの使用 Active JP7877300B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2014114.9 2020-09-08
GBGB2014114.9A GB202014114D0 (en) 2020-09-08 2020-09-08 Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
PCT/GB2021/052302 WO2022053792A1 (en) 2020-09-08 2021-09-07 Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid

Publications (3)

Publication Number Publication Date
JP2023540591A JP2023540591A (ja) 2023-09-25
JP2023540591A5 true JP2023540591A5 (cg-RX-API-DMAC7.html) 2024-09-13
JP7877300B2 JP7877300B2 (ja) 2026-06-22

Family

ID=72841287

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515363A Active JP7877300B2 (ja) 2020-09-08 2021-09-07 全身性コルチコステロイドによる治療を受けているcopd患者におけるウイルス誘導性増悪を治療するための吸入インターフェロン-ベータの使用

Country Status (7)

Country Link
US (1) US20230241177A1 (cg-RX-API-DMAC7.html)
EP (1) EP4210728A1 (cg-RX-API-DMAC7.html)
JP (1) JP7877300B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230066037A (cg-RX-API-DMAC7.html)
CN (1) CN116249545A (cg-RX-API-DMAC7.html)
GB (1) GB202014114D0 (cg-RX-API-DMAC7.html)
WO (1) WO2022053792A1 (cg-RX-API-DMAC7.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030609A (en) 1995-05-19 2000-02-29 Case Western Reserve University Method and composition for treating paramyxovirus
GB0405634D0 (en) * 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
US7871603B2 (en) 2007-05-18 2011-01-18 Synairgen Research Limited Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
JP2012512883A (ja) * 2008-12-19 2012-06-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ウイルス感染の治療における上皮成長因子阻害剤の使用
US9421243B2 (en) * 2010-03-12 2016-08-23 Synairgen Research Limited Therapy for influenza like illness
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
GB201820659D0 (en) * 2018-12-19 2019-01-30 Imperial Innovations Ltd Novel compostions and their use in therapy

Similar Documents

Publication Publication Date Title
US6297227B1 (en) Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
JP2004500429A (ja) チオトロピウム及びロフレポニドを含む医薬用の組み合わせ
JP2004500430A (ja) ホルモテロール及びブデソニドを含有する医薬用の組み合わせ
CN116033894A (zh) 用于减少气道粘膜中的病毒复制的系统、方法和药物使用
JP2023520323A5 (cg-RX-API-DMAC7.html)
US20090022671A1 (en) Treatment methods
JP2026077677A (ja) コロナウイルス感染症の処置のための方法
JP2023548647A (ja) 吸入型血管作動性腸ポリペプチドの新しい投与計画
WO2015027848A1 (zh) 含有帕拉米韦和/或其衍生物制剂的给药方法
EP3892275A1 (en) Aerosolization of hcq or its metabolites for the treatment of lung infections
JPH10500966A (ja) 経口吸入もしくは吹き込みにより投与する為の化合物、及び組成物
CN113855685A (zh) 糖皮质激素在制备治疗和/或预防呼吸道病毒感染的药物中的用途
JP2004500431A (ja) (r,r)−ホルモテロール及びロフレポニドを含む医薬組成物
JP2023535710A5 (cg-RX-API-DMAC7.html)
JP7378425B2 (ja) 肺サーファクタントおよびbpdの予防のためのステロイドを含む治療的組合せ
CN116249545A (zh) 在接受全身型皮质类固醇治疗的COPD患者中使用吸入型干扰素-β治疗病毒诱导的恶化
Kearns et al. 88 Levofloxacin pharmacokinetics (PK) after administration of MP-376 (Levofloxacin inhalation solution; Aeroquin) in children with cystic fibrosis (CF)
CN102670684A (zh) 白薇总皂苷的应用
EP4507720A1 (en) Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
CN103690934B (zh) 干扰素α与布地奈德的雾化吸入剂
HK40091740A (en) Products of manufacture and methods for treating, ameliorating or preventing microbial infections
WO2015027847A2 (zh) 含有奥司他韦羧酸胍基类似体和/或其乙酯制剂的给药方法
CN102430112A (zh) 干扰素α与硫酸沙丁胺醇的雾化吸入剂
WO2000015234A1 (en) Compositions comprising corticosteroids for treating sinusitis or otitis media
Ito et al. 90 Inhibitory effects of RV1088, a novel narrow spectrum kinase inhibitor, on RSV infection in primary bronchial epithelial cells obtained from patients with cystic fibrosis